Hussman Strategic Advisors Inc. Sells 42,000 Shares of Phibro Animal Health Corporation $PAHC

Hussman Strategic Advisors Inc. trimmed its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 33.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 84,000 shares of the company’s stock after selling 42,000 shares during the period. Hussman Strategic Advisors Inc.’s holdings in Phibro Animal Health were worth $2,145,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. LPL Financial LLC increased its position in Phibro Animal Health by 46.8% during the first quarter. LPL Financial LLC now owns 128,335 shares of the company’s stock worth $2,741,000 after buying an additional 40,889 shares during the last quarter. Kings Path Partners LLC boosted its stake in shares of Phibro Animal Health by 87.3% during the 2nd quarter. Kings Path Partners LLC now owns 20,600 shares of the company’s stock worth $526,000 after acquiring an additional 9,600 shares during the period. Voya Investment Management LLC increased its holdings in shares of Phibro Animal Health by 44.3% during the 1st quarter. Voya Investment Management LLC now owns 31,894 shares of the company’s stock worth $681,000 after acquiring an additional 9,796 shares during the last quarter. Principal Financial Group Inc. raised its stake in Phibro Animal Health by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 101,356 shares of the company’s stock valued at $2,165,000 after acquiring an additional 2,573 shares during the period. Finally, Trexquant Investment LP bought a new stake in Phibro Animal Health in the 1st quarter valued at $385,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 16,075 shares of Phibro Animal Health stock in a transaction on Monday, October 20th. The stock was sold at an average price of $40.38, for a total value of $649,108.50. Following the completion of the transaction, the chief executive officer directly owned 23,899 shares of the company’s stock, valued at $965,041.62. The trade was a 40.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 63,816 shares of company stock worth $2,582,876. 50.13% of the stock is owned by company insiders.

Phibro Animal Health Price Performance

Shares of Phibro Animal Health stock opened at $43.37 on Tuesday. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 36.75, a price-to-earnings-growth ratio of 1.24 and a beta of 0.83. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $44.35. The company has a 50-day simple moving average of $39.12 and a two-hundred day simple moving average of $30.32.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The company had revenue of $378.70 million for the quarter, compared to analysts’ expectations of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on PAHC. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Phibro Animal Health in a research report on Tuesday, October 14th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Monday, September 29th. JPMorgan Chase & Co. upgraded shares of Phibro Animal Health from a “neutral” rating to an “overweight” rating and upped their price target for the company from $25.00 to $35.00 in a research note on Monday, July 7th. Morgan Stanley set a $34.00 price objective on shares of Phibro Animal Health in a research report on Thursday, August 28th. Finally, Bank of America boosted their price objective on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a report on Friday, August 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.